The Prognostic Value of Pyrosequencing-Detected MGMT Promoter Hypermethylation in Newly Diagnosed Patients with Glioblastoma

Table 1

Demographic and clinical features of the study sample ().

Baseline characteristics
Gender, (%)
Women	18 (35%)
Men	33 (65%)
Age, years
Mean (SD)	61.7 (12.9)
Median (range)	62 (25–84)
MGMT methylation, %
Mean (SD)	21.5 (19.1)
Median (range)	16 (2–85)
Treatment history
Surgery, (%)
Done	46 (90%)
Not done	5 (10%)
Radiotherapy, (%)
Done	39 (76%)
Not done	12 (24%)
Chemotherapy, (%)
Done	41 (80%)
Not done	10 (20%)
Main outcomes
Overall survival, (%)
Dead	24 (47%)
Alive	27 (53%)
Progression-free survival
Progressed	34 (67%)
Not progressed	17 (23%)
Follow-up time, months
Mean (SD)	11.9 (6.8)
Median (range)	12 (3–27)

Follow-up time refers to time from disease diagnosis and death or last visit.